Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96LR5

UPID:
UB2E2_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme E2; UbcH8; Ubiquitin carrier protein E2; Ubiquitin-protein ligase E2

ALTERNATIVE UPACC:
Q96LR5

BACKGROUND:
Ubiquitin-conjugating enzyme E2 E2, also referred to as UbcH8, Ubiquitin carrier protein E2, and Ubiquitin-protein ligase E2, is integral to the ubiquitin-proteasome system. It is responsible for the transfer of ubiquitin from the E1 complex to substrates, enabling 'Lys-11'-, 'Lys-48'-, and 'Lys-63'-linked polyubiquitination. Its activity is crucial for the ISGylation process of the influenza A virus NS1 protein, indicating its significant role in immune response and viral pathogenesis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Ubiquitin-conjugating enzyme E2 E2 offers a promising avenue for the development of novel therapeutic approaches, especially in the realms of viral defense mechanisms and protein homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.